Scleroderma (Systemic Sclerosis, SSc) is a devastating multiorgan disease with a prevalence of approximately 250 cases per million people in the US. The hallmark features of SSc include fibroproliferative vasculopathy, immune dysfunction, and extensive skin and organ fibrosis. Despite extensive clinical and pathological findings concerning vascular dysfunction, the mechanism underlying vascular disease and the relationship between vasculopathy and other disease manifestations is poorly understood. The progress in this area is hampered by the heterogeneity of the disease and the lack of the animal models that adequately represent the complex nature of SSc. Based on extensive studies that implicated deficiency of transcription factor Fli1 in SSc vasculopathy and fibrosis, we have established a transgenic model of SSc that recapitulates many of the vascular features of SSc and shows evidence of increased susceptibility to fibrosis. In addition, we developed an inducible model of dermal fibrosis based on Angiotensin II infusion that is characterized by vascular injury, inflammation and fibrosis, thus recapitulating the principal features of SSc. The proposed studies will test the hypothesis that persistent endothelial cell injury, in part mediated through activation of the TLR4/PKC?/Fli1 pathway, is a key pathogenic event that leads to myofibroblast activation and fibrosis in SSc. The studies will include investigation of the molecular mechanisms of LPS/TLR4 induced endothelial-mesenchymal transition (EndMT), with the emphasis on the PKC?-Fli1 axis combined with the comprehensive analyses of the new SSc mouse models. To further substantiate the pathological role of the PKC?/Fli1 pathway we will determine whether blockade of this pathway is therapeutically effective in reducing vasculopathy and fibrosis in animal models of SSc. We propose the following specific aims: 1: To determine the molecular mechanism of LPS/TLR4-induced activation of endothelial cells focusing on the role of PKC?/Fli1 as mediators of this process. 2: To elucidate the relationship between vasculopathy and fibrosis using mouse models of SSc. 3: To determine the therapeutic potential of novel PKC? inhibitors in reducing vasculopathy and fibrosis in vivo.

Public Health Relevance

We have successfully established experimental models of SSc recapitulating the key disease features, including vasculopathy and fibrosis that will allow us to begin to address some of the unanswered questions related to the pathogenesis of SSc and characterize candidate molecules and pathways in SSc. The new knowledge generated by these studies will help to unravel the molecular basis of the vascular injury and the relationship between vasculopathy and fibrosis and ultimately provide logical and effective targets for therapeutic intervention in SSc.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Research Project (R01)
Project #
Application #
Study Section
Arthritis, Connective Tissue and Skin Study Section (ACTS)
Program Officer
Tseng, Hung H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Boston University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Han, Rong; Pacifici, Maurizio; Iwamoto, Masahiro et al. (2015) Endothelial Erg expression is required for embryogenesis and vascular integrity. Organogenesis 11:75-86
Taniguchi, Takashi; Asano, Yoshihide; Akamata, Kaname et al. (2015) Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. Arthritis Rheumatol 67:517-26
Akamata, Kaname; Asano, Yoshihide; Yamashita, Takashi et al. (2015) Endothelin receptor blockade ameliorates vascular fragility in endothelial cell-specific Fli-1-knockout mice by increasing Fli-1 DNA binding ability. Arthritis Rheumatol 67:1335-44
Farina, Antonella; Cirone, Mara; York, Michael et al. (2014) Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma. J Invest Dermatol 134:954-64
van Bon, Lenny; Affandi, Alsya J; Broen, Jasper et al. (2014) Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 370:433-43
Stawski, Lukasz; Haines, Paul; Fine, Alan et al. (2014) MMP-12 deficiency attenuates angiotensin II-induced vascular injury, M2 macrophage accumulation, and skin and heart fibrosis. PLoS One 9:e109763
Kudo, Hideo; Jinnin, Masatoshi; Asano, Yoshihide et al. (2014) Decreased interleukin-20 expression in scleroderma skin contributes to cutaneous fibrosis. Arthritis Rheumatol 66:1636-47
Lenna, Stefania; Han, Rong; Trojanowska, Maria (2014) Endoplasmic reticulum stress and endothelial dysfunction. IUBMB Life 66:530-7
Noda, Shinji; Asano, Yoshihide; Nishimura, Satoshi et al. (2014) Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun 5:5797
Chrobak, Izabela; Lenna, Stefania; Stawski, Lukasz et al. (2013) Interferon-γ promotes vascular remodeling in human microvascular endothelial cells by upregulating endothelin (ET)-1 and transforming growth factor (TGF) β2. J Cell Physiol 228:1774-83

Showing the most recent 10 out of 57 publications